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ABSTRACT
Objectives Develop recommendations for women’s
health issues and family planning in systemic lupus
erythematosus (SLE) and/or antiphospholipid syndrome
(APS).
Methods Systematic review of evidence followed by
modiﬁed Delphi method to compile questions, elicit expert
opinions and reach consensus.
Results Family planning should be discussed as early as
possible after diagnosis. Most women can have successful
pregnancies and measures can be taken to reduce the risks
of adverse maternal or fetal outcomes. Risk stratiﬁcation
includes disease activity, autoantibody proﬁle, previous
vascular and pregnancy morbidity, hypertension and
the use of drugs (emphasis on beneﬁts from
hydroxychloroquine and antiplatelets/anticoagulants).
Hormonal contraception and menopause replacement
therapy can be used in patients with stable/inactive disease
and low risk of thrombosis. Fertility preservation with
gonadotropin-releasing hormone analogues should be
considered prior to the use of alkylating agents. Assisted
reproduction techniques can be safely used in patients with
stable/inactive disease; patients with positive
antiphospholipid antibodies/APS should receive
anticoagulation and/or low-dose aspirin. Assessment of
disease activity, renal function and serological markers is
important for diagnosing disease ﬂares and monitoring
for obstetrical adverse outcomes. Fetal monitoring
includes Doppler ultrasonography and fetal biometry,
particularly in the third trimester, to screen for placental
insufﬁciency and small for gestational age fetuses.
Screening for gynaecological malignancies is similar to
the general population, with increased vigilance for
cervical premalignant lesions if exposed to
immunosuppressive drugs. Human papillomavirus
immunisation can be used in women with stable/inactive
disease.
Conclusions Recommendations for women’s health
issues in SLE and/or APS were developed using an
evidence-based approach followed by expert
consensus.
INTRODUCTION
Systemic lupus erythematosus (SLE) and the anti-
phospholipid syndrome (APS), SLE-associated or
primary APS, affect mostly women of childbearing
age. Several ‘unmet needs’ in the management of
reproductive and other women’s health issues may
impact on personal relationships and the decision
to have children.1 Because of earlier recognition
of disease and advances in medical treatment,
family planning has gained greater importance.2–4
Concerns include the effect of pregnancy on mater-
nal disease, the impact of disease activity on fetal
health and the safety of medications during preg-
nancy and breast feeding. Assessment of fertility
and feasibility of assisted reproduction techniques
(ARTs), use of contraception, management of
menopause and surveillance against malignancies
need to be addressed. We gathered a multidiscip-
linary panel of experts to develop evidence-
based recommendations on the management of
family planning and women’s health issues in
SLE and/or APS.
METHODS
We followed the European League Against
Rheumatism (EULAR) standardised operating pro-
cedures5 and the Appraisal of Guidelines Research
and Evaluation instrument. Through a Delphi-
based approach, the committee selected 12 research
questions further edited for systematic literature
review (see online supplementary table S1). We
searched PubMed using arrays of relevant terms; all
English-language publications up to December
2014 were considered. A hand search was also per-
formed in October 2015. Retrieved items were
reﬁned based on abstract, full-text content and
number of included patients. A detailed presenta-
tion of the literature review is given in the online
supplementary table S2. Evidence was categorised
based on the design and validity of available studies
and the strength of the statements was graded (see
online supplementary table S3). After rounds of
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Table 1 Recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in
patients with systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS)
LoA
Statement/recommendation Mean (SD) Median (IQR)
1. Preconception counselling and risk stratification
1.1 In women with SLE, major risk factors for adverse maternal and fetal outcomes include active/flaring SLE (1/A), especially active nephritis
(1/A), history of lupus nephritis (2/B) and presence of aPL/APS* (1/A).
1.1.1 Blood pressure monitoring (2/B), use of safe medications to control disease activity (emphasis on HCQ (2/B)) and limiting glucocorticoids
exposure (2/B) are essential measures.
1.2 In women with APS (primary or SLE-APS), risk factors include high-risk aPL profile (lupus anticoagulant, multiple aPL, moderate to high
titre aPL) (1/A), coexisting SLE (2/B), history of vascular/thrombotic APS (2/B) and of previous adverse pregnancy complications (2/B).
1.2.1 Blood pressure monitoring (3/C) and use of antiplatelet and/or anticoagulant therapy (rated at statement 9) are of fundamental
importance.
10 (0.2) 10 (0)
2. Contraceptive measures
2.1 Women with SLE should be counselled about the use of effective contraceptive measures (oral contraceptives, subcutaneous implants, IUD),
based on their disease activity and thrombotic risk (particularly aPL status). IUD can be offered to all the patients with SLE and/or APS free
of any gynaecological contraindication (1/A).
2.2 In patients with stable/inactive SLE and negative aPL, combined hormonal contraceptives can be considered (1/A). In women with positive
aPL with or without definite APS, hormonal contraception (with progesterone only) must be carefully weighed against the risk of thrombosis
(2/B).
9.9 (0.4) 10 (0)
3. Risk factors for reduced fertility
Women with SLE who wish to plan a pregnancy should be counselled about fertility issues, especially the adverse outcomes associated with
increasing age and the use of alkylating agents (1/A). Treatment with alkylating agents should be balanced against the risk of ovarian
dysfunction.
9.8 (0.4) 10 (0)
4. Preservation of fertility
Fertility preservation methods, especially GnRH analogues, should be considered for all menstruating women with SLE who are going to
receive alkylating agents (2/B).
9.5 (0.7) 10 (1)
5. Assisted reproduction techniques
5.1 Assisted reproduction techniques, such as ovulation induction treatments and in vitro fertilisation protocols, can be safely used in patients
with SLE with stable/inactive disease (3/C).
5.2 Patients with positive aPL/APS should receive anticoagulation (at the dosage as would be recommended during pregnancy) and/or low-dose
aspirin (3/D).
9.6 (0.6) 10 (1)
6. Predictive biomarkers for maternal disease activity in SLE pregnancy
In pregnant women with SLE, assessment of disease activity (1/A)—including renal function parameters (2/B) and serological markers
(serum C3/C4, anti-dsDNA titres) (2/B)—is recommended to monitor for obstetrical adverse outcomes and disease flares.
9.9 (0.3) 10 (0)
7. Pregnancy monitoring
7.1 Women with SLE and/or APS should undergo supplementary fetal surveillance with Doppler ultrasonography and biometric parameters,
particularly in the third trimester to screen for placental insufficiency and small for gestational age fetuses (3/D).
7.2 Fetal echocardiography is recommended in cases of suspected fetal dysrhythmia or myocarditis, especially in patients with positive anti-Ro/
SSA and/or anti-La/SSB antibodies (2/C)†.
9.7 (0.5) 10 (1)
8. Drugs for the prevention and management of SLE flares during pregnancy
8.1 HCQ (1/B), oral glucocorticoids, azathioprine, ciclosporin A and tacrolimus (all 3/C) can be used to prevent or manage SLE flares during
pregnancy.
8.2 Moderate-to-severe flares can be managed with additional strategies, including glucocorticoids intravenous pulse therapy, intravenous
immunoglobulin and plasmapheresis (all 3/C).
8.3 Mycophenolic acid, cyclophosphamide, leflunomide and methotrexate should be avoided.
9.7 (0.7) 10 (0)
9. Adjunct treatment during pregnancy
9.1 HCQ is recommended preconceptionally and throughout pregnancy for patients with SLE (2/B).
9.2 Women with SLE at risk of pre-eclampsia (especially those with lupus nephritis or positive aPL) should receive LDA (2/C). In women with
SLE-associated APS or primary APS, combination treatment with LDA and heparin is recommended to decrease the risk of adverse pregnancy
outcomes (1/A).
9.3 Supplementation with calcium, vitamin D and folic acid should be offered as in the general population (–/D). Measuring blood vitamin D
levels should be considered after pregnancy is confirmed (–/D).
9.8 (0.4) 10 (0)
10. Menopause and HRT
HRT can be used for the management of severe vasomotor menopausal manifestations in SLE women with stable/inactive disease and
negative aPL (1/A). The use of HRT in patients with positive aPL should be carefully weighed against the risk of thrombosis and
cardiovascular disease (–/D).
9.6 (0.6) 10 (1)
11. Screening for malignancies
Women with SLE and/or APS should undergo screening for malignancies similar to the general population (–/D). Women with SLE, especially
those exposed to immunosuppressive drugs, are at higher risk of cervical premalignant lesions and should be monitored with vigilance (2/B).
9.8 (0.4) 10 (0)
12. HPV vaccination
HPV immunisation can be considered in women with SLE and/or APS and stable/inactive disease (3/D).
9.2 (1.6) 10 (1)
For each statement or item, the LoE (range 1–3) and the GoR (range A–D) is given in parentheses (refer to online supplementary table S1). In the right-hand columns, the LoA among
experts is reported as mean (SD) and median (IQR) values. A score of 10 represents the highest level of agreement.
*aPL and APS are defined according to the updated international consensus criteria.6 For aPL assays, please see the footnotes of table 2.
†The substatement on fetal echo in women with SLE/APS and positive anti-Ro/La is rated with LoE=2 (ie, sufficient evidence for the association between anti-Ro/La and congenital heart
block) but GoR=C due to lack of strong evidence for the clinical implications of this association, namely for the efficacy of interventions.
anti-dsDNA, anti-double-stranded DNA antibodies; aPL, antiphospholipid antibodies; GnRH, gonadotropin-releasing hormone; GoR, grade of recommendation; HCQ, hydroxychloroquine;
HPV, human papillomavirus; HRT, hormone replacement therapy; IUD, intrauterine devices; LDA, low-dose aspirin; LoA, level of agreement; LoE, level of evidence.
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discussions, the committee arrived at 12 ﬁnal statements (table 1).
Each member rated her/his agreement with each statement.
RESULTS AND DISCUSSION
Scope and overarching principles
These recommendations have been devised with the intention
of helping physicians involved in the care of patients with SLE
and/or APS and facilitating physician–patient communication.
They recognise an implicit need for change in the mindset of
health professionals, shifting from caution against pregnancy
towards embracement of pregnancy. Accordingly, family plan-
ning should be discussed from the ﬁrst physician–patient
encounter and reinforced thereafter. Health professionals
should support the patient and her family in their decisions
regarding family planning by discussing individual pregnancy
risks. Reports on the long-term follow-up of SLE and/or APS
offspring are few,7–10 showing a reassuring picture on the health
conditions of the children, with the exception of some cases of
neurodevelopmental alterations11–13 that need further conﬁrm-
ation before they are linked to maternal disease.
Recommendations
Preconception counselling and risk stratiﬁcation
Assessment of risk factors for adverse maternal and fetal out-
comes in pregnant women with SLE and/or APS is crucial for
preconception counselling and implementing appropriate
preventive strategies and patient-tailored monitoring plan before
and during pregnancy (table 2).
In SLE women (with or without APS), prematurity, pre-
eclampsia and eclampsia/Hemolysis, Elevated Liver enzyme
levels, Low Platelet count (HELLP) rates approximate 25–35%,
10–15% and 1.0–1.5%, respectively.19 24 25 44 51 52 In APS
women (primary or SLE-related), the respective frequencies
approximate 25–35%, 10–20% and 3.0–5.0%.28 29 53 54
During pregnancy, risk factors associated with adverse out-
comes include active/ﬂaring SLE (OR 12.7 for pre-eclampsia/
eclampsia;55 19.0 for emergency caesarean section;56 3.0 for
early fetal loss;20 5.5 for preterm delivery),21 19 active nephritis
(OR 5.3 for any adverse maternal outcome),57 hypertension
(OR 4.8–7.3 for pre-eclampsia;52 relative risk (RR) 1.8 for
preterm birth)22 and use of glucocorticoids, especially at main-
tenance dose ≥10–20 mg/day of prednisone equivalent (OR 3.5
for preterm birth).58 59 Discontinuation of hydroxychloroquine
(HCQ) is related to an increased risk for SLE exacerbations
during pregnancy,24 33 56 and a single placebo-controlled study
has suggested a beneﬁcial effect of HCQ on maternal disease
activity during pregnancy.60
Contraceptive measures
Women with SLE and/or APS should be counselled about
contraception, especially for the prevention of unwanted preg-
nancies during high disease activity periods and intake of terato-
genic drugs. Effective contraceptive measures should be
Table 2 Checklist of parameters to be considered for preconception counselling and risk stratification in women with systemic lupus
erythematosus (SLE) and/or antiphospholipid syndrome (APS)
Disease-related risk factors Prognostic implications
SLE activity/flares* (in the last 6–12 months
or at conception)
Increased risk for (i) maternal disease activity (RR 2.1 for subsequent flare during pregnancy and puerperium);14
(ii) hypertensive complications (OR 1.8 for PE);15 (iii) fetal morbidity and mortality (OR 5.7 for pregnancy loss,16 3.5 for
IUGR17 6.5 for preterm delivery)14 15 17–22
Lupus nephritis (history or active at
conception†)
Strong predictor of poor maternal (RR 9.0 for renal flare during/after pregnancy)23 and fetal outcome(s) (OR 7.3 for fetal loss
and 18.9 for preterm delivery)24 25
Serological (serum C3/C4, anti-dsDNA titres)
activity
Increased risk for maternal SLE flares during pregnancy (OR 5.3)14 and pregnancy loss23 26 27
Previous adverse pregnancy outcome(s) APS: increased risk for pregnancy complications28–30
History of vascular thrombosis APS: increased risk (ORs ranging 3.6–12.7) for pregnancy morbidity31
SLE diagnosis APS: increased risk (OR 6.9) for pregnancy morbidity31 32
aPL profile‡ SLE: strong predictor of adverse maternal and fetal outcomes,19 25 27 33 34 especially for patients with persistent
moderate-to-high aPL titres, LA and multiple aPL positivity (high-risk aPL profile)
APS: high-risk aPL profile correlates with increased risk of maternal vascular thrombotic events during pregnancy (OR 12.1),35
(pre-)eclampsia (OR 2.3),36 37 APS-related pregnancy morbidity (OR 9.2),31 IUGR (OR 4.7),36 preterm birth38 39
Anti-Ro/SSA, anti-La/SSB antibodies Linked to development of neonatal lupus, including a low risk (0.7–2%) for CHB (especially if moderate-to-high anti-Ro
titres);40–43 weak association with other pregnancy complications44
End-stage organ damage and associated
comorbidities
45 46
General risk factors 47
Maternal age
Arterial hypertension Increased risk for pregnancy loss (OR 2.4,33 RR 2.9),48 preterm birth18 24 27 and IUGR (OR 6.8)15
Diabetes mellitus 49
Overweight/obesity
Thyroid disease 50
Nicotine and alcohol use 28
Immunisations§
*Diagnosed by validated SLE activity indices and/or physician judgement.
†Evaluated by renal function tests (serum creatinine, blood urea nitrogen) and urinalysis (proteinuria urine sediment).
‡Includes LA, aCL IgG/IgM, aβ2GPI IgG/IgM. The level of positivity of aCL and aβ2GPI antibodies (low vs medium–high) should be defined according to the single assay’s characteristics.
§If negative serology, evaluate whether immunisations can be performed prior to pregnancy (eg, rubella).
aCL, anticardiolipin antibodies; aβ2GPI, anti-β2-GPI antibodies; anti-dsDNA, anti-double-stranded DNA antibodies; aPL, antiphospholipid antibodies; CHB, congenital heart block; IUGR,
intrauterine growth restriction; LA, lupus anticoagulant; PE, pre-eclampsia; RR, relative risk.
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discussed with the patient by weighing the individual risk
factors, including general (hypertension, obesity, tobacco use,
family history of hormonal-dependent cancers)61 and disease-
related risk factors, particularly disease activity and thrombotic
risk (emphasis on antiphospholipid antibodies (aPLs)).
The intrauterine device (IUD) can be offered to all patients
unless there is a gynaecological contraindication. Copper IUD
can be used in any patient, while levonorgestrel-containing IUD
should be considered only if the beneﬁts of the released
hormone (such as the reduction of excessive menstrual bleeding
due to anticoagulation)62 outweigh the risk of thrombosis.61
The safety of the combined (oestrogen plus progestin) and
progestin-only pill in SLE patients with inactive or stable
active SLE and negative aPL has been demonstrated in rando-
mised controlled trials (RCTs).63 64 In women with positive aPL
(with or without deﬁnite APS), contraception with combined
hormones (oral pill, vaginal ring, transdermal patch) should be
discouraged. In young women with myocardial infarction or
ischaemic stroke and positive lupus anticoagulant, the use of the
combined pill increased the risk of arterial events compared
with non-users.65 In fully anticoagulated patients carrying a
low-risk aPL proﬁle, oestrogens might be considered for persist-
ent gynaecological disorders not otherwise managed. Compounds
containing progestin only (pill, subcutaneous depot injections)
are suitable for these women, although their use should be
weighed against the risk of thrombosis. Progestin-only emer-
gency contraception is not contraindicated in patients with SLE
and/or APS.
Risk factors for reduced fertility
Few studies have assessed fertility in women with SLE and/or
APS by means of hormonal levels (including the anti-Müllerian
hormone) or antral follicle count (examined by ultrasound).
There is no concrete evidence that the disease per se decreases
fertility.66–69
However, active disease, especially lupus nephritis, and the
use of immunosuppressive drugs may negatively impact on fer-
tility. Alkylating agents such as cyclophosphamide (CYC) may
cause menstrual irregularities and premature ovarian failure
(POF), which is age- and dosage dependent.70 71
Similar to the general population, women with SLE and/or
APS should be counselled on fertility issues, especially on the
negative impact of increasing age (general tendency to postpone
childbearing) and certain lifestyle exposures (tobacco use,
alcohol consumption). In non-life-threatening disease, treatment
with alkylating agents should be balanced against the risk of
ovarian dysfunction; rather, less gonadotoxic regimens should
be considered.72 In the presence of multiple risk factors for
impaired fertility, ovarian reserve may be assessed in patients
with SLE at a younger age than recommended for the general
population.73
Fertility preservation
Limited data are available on fertility preservation methods in
menstruating women with SLE who require treatment with
alkylating agents. Cryopreservation of ovarian tissue or oocytes/
embryos are poorly investigated options74 75 and require specia-
lised centres, which may not be easily accessible.
The most extensively studied method for POF prevention in
patients with SLE involves gonadotropin-releasing hormone
analogues (GnRH-a), with a good safety and efﬁcacy proﬁle
(RR 0.12).76 GnRH-a have been efﬁcacious in patients with
cancer.77 78 GnRH-a are likely to protect against POF, but there
are no data on subsequent pregnancies in patients with SLE.
They can cause menopause-like symptoms, which are fully
reversible upon discontinuation. A study in childhood-onset
patients with SLE aged <21 years suggested that GnRH-a
should be administered 22 days before CYC is started or contin-
ued.79 It is nevertheless recommended to start the GnRH-a
prior to or concomitantly to initiation of the alkylating agent.
Assisted reproduction techniques
Evidence on the efﬁcacy and safety of ARTs (ovulation induction
therapy and in vitro fertilisation) in women with SLE and/or
APS comes from observational studies.80–83 Efﬁcacy in terms of
pregnancy rate is comparable with that in the general population
(up to 30%). ARTs are generally safe if the patient has quiescent
disease and is on appropriate antithrombotic treatment if aPL
positive. Although it is challenging to deﬁne a single protocol,
some general measures for prophylaxis in aPL-positive women
undergoing ovarian stimulation can be suggested. The type
(low-dose aspirin (LDA); low molecular weight heparin
(LMWH)) and dosage (prophylactic vs full anticoagulant) of
antithrombotic treatment should be recommended as during
pregnancy according to the individual risk proﬁle. LDA should
be stopped three days before egg retrieval and resumed the fol-
lowing day. Patients taking LMWH should stop it at least
12 hours prior to the procedure and resume it the very same
day as long as there is no bleeding. Patients with positive aPL
who are not taking LDA during the ovarian stimulation period
should start LDA on the day of the embryo transfer, usually in
combination with LMWH (which will be continued during
pregnancy).
Ovarian hyperstimulation syndrome can be avoided by milder
hormonal stimulation or GnRH antagonist protocol.84 The use
of the ‘natural cycle’ method is another option, although
associated with a lower rate of induced pregnancy. The ART
induction protocol should be tailored to the individual patient,
balancing the safety and effectiveness of the procedure.
Predictive biomarkers for maternal disease activity
in SLE pregnancy
Active SLE during pregnancy, assessed by validated disease
activity indices22 56 and/or physician global assessment,20 is
associated with increased risk for maternal and/or fetal compli-
cations (see also paragraph on Preconception counselling and
risk stratiﬁcation). Pregnancy-speciﬁc SLE activity indices have
been developed and validated for their sensitivity in detecting
changes in disease activity and diagnosing ﬂares (see online sup-
plementary table S4).85 86 Physicians should be aware of preg-
nancy physiological changes that can resemble SLE symptoms
and signs.87 Renal activity correlates with adverse pregnancy
outcomes and should be monitored by means of urine protein
excretion, urine sediment analysis (glomerular haematuria,
urinary casts) and serum creatinine level/glomerular ﬁltration
rate.33 49 52 Serological markers are useful in monitoring SLE
activity and in the differentiation between disease exacerbation
(declining serum C3/C4 levels (even within the normal range)
and/or increasing anti-double stranded DNA titres) and pre-
eclampsia.88 89 Smaller increases in serum C3 levels from preg-
nancy onset to the second or third trimester19 as well as sero-
logical activity (as deﬁned above) that develops during
pregnancy, especially in the context of clinical SLE activity, have
been associated with increased risk for pregnancy loss,19 90
intrauterine growth restriction (IUGR)91 and preterm
birth.19 48 89 90 92
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Pregnancy monitoring
Pregnant women with SLE and/or APS should follow the local
protocols applied to pregnancies at high risk for hypertensive
disorders and/or placental insufﬁciency, adjusting the frequency
and modality of fetal surveillance according to the maternal
and/or fetal status (box 1). Fetal surveillance based on biometric
and Doppler ﬁndings during the third trimester, and particularly
the distinction between early and late IUGR, helps to better
tailor the time of delivery and reduce perinatal morbidity and
mortality.93–97 Umbilical and uterine arteries Doppler sonog-
raphy at 20–24 weeks has good negative predictive value but
modest positive predictive value (especially in the absence of
biometric signs of fetal growth restriction later in pregnancy)
for placental-associated pregnancy disorders such as pre-
eclampsia and IUGR. The mode (vaginal vs caesarean section)
and timing of delivery are inﬂuenced by maternal (hypertensive
disorders, anticoagulation status) as well as fetal conditions
during pregnancy.
Fetal echocardiography is indicated if there is suspected fetal
dysrhythmia or myocarditis, especially in the context of positive
maternal anti-Ro/SSA or anti-La/SSB antibodies. Other tests
(electrocardiogram plus Holter monitor, magnetocardiography,
gated-pulsed Doppler technique, velocity-based fetal kinetocar-
diogram) might detect subtle signs of the development of con-
genital heart block (CHB), but are not currently recommended
as standard practice.98 CHB associated with anti-Ro/SSA and/or
anti-La/SSB has 16% recurrence rate in women with a previ-
ously affected child; therefore, it is recommended to perform
serial fetal echocardiograms weekly from 16 weeks of gestation
onwards.98 Considering the low risk (0.7–2%) for CHB in
women with no previous CHB, it is unclear whether intensive
monitoring (weekly/biweekly between 16 and 26 weeks of gesta-
tion and less frequently afterwards)98 in the general population
of anti-Ro/La-positive women is cost-effective. Moreover, there
is no proven efﬁcacy of protocols for the prevention or treat-
ment of complete CHB.99 100 The efﬁcacy of maternal ﬂuori-
nated steroids has not been established in large cohorts101–104
despite initial reports of favourable effects in cases of incom-
plete CHB, cardiomyopathy, endocardial ﬁbroelastosis and
hydrops fetalis.99 Given the potential of ﬂuorinated steroids for
major maternal and fetal side effects, the beneﬁt for fetuses with
CHB should be stratiﬁed according to the presence of risk
factors for adverse outcome.99 Despite its unproven beneﬁt, the
current practice of intensive surveillance for CHB onset in
women with positive anti-Ro/SSA and/or anti-La/SSB antibodies
and no previous child affected by CHB carries no risk and is
well accepted by the mothers.105
Drugs for prevention and management of SLE ﬂares during
pregnancy
A single randomised, placebo-controlled study60 as well as non-
randomised evidence24 33 56 supports the beneﬁcial role of
HCQ in controlling disease activity and preventing ﬂare-ups
during pregnancy. Uncontrolled studies suggest an acceptable
beneﬁt/risk ratio of oral glucocorticoids,22 106 azathioprine59 107
and calcineurin inhibitors (ciclosporin A, tacrolimus)108 109 in
controlling SLE activity during pregnancy. In moderate-to-severe
ﬂares, additional modalities can be considered, such as high-dose
glucocorticoids (including pulse intravenous therapy),110 111 intra-
venous immunoglobulin20 22 and plasmapheresis (may be also
used in refractory nephrotic syndrome).112 113 CYC should not
be administered during the ﬁrst trimester of pregnancy due to
risk for fetal loss (OR 25.5)20 114 and should be reserved only for
the management of severe, life-threatening or refractory SLE
manifestations during the second or third trimester. Available data
are not sufﬁcient to evaluate the risk of using belimumab in preg-
nancy115 and the drug should not be used unless the beneﬁt out-
weighs the risk to the fetus. Mycophenolic acid, methotrexate
and leﬂunomide should be avoided due to known or possible
teratogenicity.116 To this end, collaborative groups have developed
recommendations for the use of antirheumatic drugs before and
during pregnancy and lactation.111 117 118
Adjunct treatment during pregnancy
Use of HCQ is recommended in women with SLE preconcep-
tionally and throughout pregnancy.33 56 60 A beneﬁcial role has
also been suggested for APS pregnancies,119–121 but at present
there is insufﬁcient data to recommend its routine use in these
patients. HCQ may reduce the odds of CHB occurrence in
fetuses exposed to maternal anti-Ro/SSA antibodies, especially
in mothers who already had a child with CHB.40 122
The protective role of LDA against preterm and severe pre-
eclampsia has been established in non-autoimmune patients.123 124
Accordingly, women with SLE at higher risk of pre-eclampsia
including those with lupus nephritis or positive aPL will beneﬁt
from LDA, preferably given preconceptionally or no later than
gestational week 16.123 124
In women with deﬁnite obstetric APS, combination treatment
with LDA and heparin is recommended to decrease the risk of
adverse pregnancy outcomes.16 125–127 Statistically signiﬁcant
results have been demonstrated only for unfractionated heparin
in RCTs. However, LMWH is preferable for practical reasons
and has shown comparable efﬁcacy in prospective studies.128 129
Moreover, patients with positive aPL but with no deﬁnite classi-
ﬁcation of APS will beneﬁt from combination therapy if they are
considered at moderate to high risk of maternal and fetal com-
plications (see online supplementary table S5).
In addition, other regimens such as prednisolone 10 mg/day
in the ﬁrst trimester, intravenous immunoglobulin or plasma-
pheresis can be considered for selected patients with APS
(refractory obstetric APS, women with previous thrombosis, par-
ticularly previous or new cerebrovascular events, women with
triple aPL positivity).119 130–133
Box 1 Ultrasonographic fetal surveillance recommended
for pregnant women with systemic lupus erythematosus
and/or antiphospholipid syndrome43 45–48
▸ Routine ultrasonographic screening
– First trimester (11–14 weeks of gestation).
– Second trimester (with Doppler, preferably at
20–24 weeks of gestation).
▸ Supplementary fetal surveillance in the third trimester at
monthly intervals
– Doppler sonography of the umbilical artery, uterine
arteries, ductus venosus and middle cerebral artery
(particularly in fetuses that have been identiﬁed to suffer
from early intrauterine growth restriction (IUGR), ie, prior
to 34 weeks of gestation).
– In cases of late IUGR (diagnosed after 34 weeks), reduced
abdominal circumference growth velocity and/or a
reduced cerebroplacental ratio at Doppler investigation
was shown to identify fetuses at higher risk of poor
perinatal outcome (Doppler of the umbilical artery alone
is insufﬁcient).
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As recommended in the general population, supplementation
with calcium, vitamin D and folic acid should be offered to
patients with SLE and/or APS, with particular consideration to
those with low circulating levels of 25-OH vitamin D in the ﬁrst
trimester of gestation and receiving glucocorticoids and/or
heparin for their detrimental effects on bone mass.
Menopause and hormone replacement therapy
The efﬁcacy and safety of hormone replacement therapy (HRT)
(oestrogen plus progestin) in selected patients with SLE has
been illustrated in RCTs.134–136 Beneﬁt was demonstrated
mainly in vasomotor and other hypoestrogenism symptoms. No
signiﬁcantly increased risk of severe lupus exacerbations during
12–24 months of HRTwas found, although there was a modest
increase in mild-to-moderate ﬂares.132 There was no increased
risk of thrombosis and cardiovascular events, although one of
the RCTs included only patients with negative aPL and no previ-
ous cardiovascular events132 and another did not detail the aPL
proﬁle.63 Two cohort studies with long-term follow-up did not
report signiﬁcantly increased risk of cardiovascular events
during HRT,137 138 although limitations in power and design
preclude ﬁrm conclusions. Consequently, HRT should be
reserved for the management of severe and disabling vasomotor
menopausal symptoms, preferably in SLE women with stable/
inactive disease and negative aPL. In patients with positive aPL,
the use of HRT should be carefully weighed against thrombotic
and cardiovascular risks. If menopause symptoms necessitate
HRT, it seems reasonable to start it as early as possible to gain
an added beneﬁt for bone protection.139 Optimal duration of
HRT in patients with SLE and/or APS is not known, but it
seems reasonable to recommend it for the shortest possible
duration.140 141
Screening for malignancies
Women with SLE are not at increased risk of breast, ovarian and
endometrial cancer compared with the general population,142 143
and, therefore, should follow the current population screening
protocols for these malignancies. Conversely, women with SLE
are at higher risk of cervical dysplasia (but not cervical
cancer),144–147 vagina and vulva cancers,142 147 likely associated
with human papillomavirus (HPV) infection. Women with SLE
exposed to immunosuppressive drugs, particularly CYC in a
cumulative dose-dependent fashion, are at higher risk of cervical
dysplasia.148–151 The suggested timing for Papanicolaou (PAP)
smear examination would be once a year in heavily immunosup-
pressed patients or according to the local screening programme
in low-risk patients. Subgroups of women with SLE (Caucasian,
younger age, lower education, high SLE damage) may be at risk
for poorer adherence to screening programmes.152 153
HPV vaccination
HPV vaccination is currently offered to female and male adoles-
cents for preventing precancerous growths and cancer in the
cervix and in the genital area. There are reports of venous
thromboembolic events (VTEs) associated with the quadrivalent
HPV vaccine. However, of the 31 cases (0.2/100 000 doses
vaccine) with documented VTE, 90% had a known risk factor
for VTE (APS in two cases).154
Prospective studies have demonstrated efﬁcacy and safety of
HPV vaccination in patients with SLE,155 156 although seroconver-
sion rates may be lower in patients receiving steroids and immuno-
suppressive agents. A few cases of severe SLE ﬂares or abrupt SLE
onset after HPV vaccination have been reported.157–159 In accord-
ance with the EULAR recommendations,160 we recommend that
HPV vaccination be offered to young women with stable/inactive
SLE and/or APS, according to local protocols, with particular
caution in those with high-risk aPL proﬁle.
The points to consider and the research agenda suggested by
the Task Force Members are reported in box 2.
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Box 2 Points to consider and research agenda
▸ Reproductive issues are of paramount importance for women
with systemic lupus erythematosus (SLE) and/or
antiphospholipid syndrome (APS) and should be addressed
on a regular basis by healthcare providers.
▸ Preconception counselling and risk stratiﬁcation are essential
for prevention of unwanted complications during pregnancy.
▸ The use of hormonal contraception or replacement therapy is
feasible but must be weighed against the individual risk of
thrombosis.
▸ The preservation of fertility should be mentioned while
counselling about lifestyles and considered in the treatment
choice. Validated protocols for assisted reproduction
techniques in patients with SLE and/or APS are needed.
▸ Predictive biomarkers for maternal disease activity during
SLE pregnancy should be expanded with particular focus on
the prediction of pre-eclampsia.
▸ Pregnancy monitoring in SLE and/or APS women should aim
at the identiﬁcation of placental insufﬁciency with fetal
growth restriction in order to decide the best timing for
delivery and reduce the risk of perinatal morbidity and
mortality.
▸ The cost-effectiveness of intensive surveillance with fetal
echocardiography in patients with positive anti-Ro/SSA and
anti-La/SSB antibodies and no previous child with congenital
heart block remains to be established.
▸ Hydroxychloroquine is beneﬁcial during pregnancy to reduce
the risk of SLE ﬂares and of poor obstetrical outcomes. More
data are needed to support its beneﬁt in APS pregnancies.
▸ The beneﬁts of cancer surveillance and prevention of
gynaecological malignancies need to be communicated to
patients.
Recommendations
481Andreoli L, et al. Ann Rheum Dis 2017;76:476–485. doi:10.1136/annrheumdis-2016-209770
group.bmj.com on May 10, 2017 - Published by http://ard.bmj.com/Downloaded from 
17Unit of Obstetrics and Gynaecology, Spedali Civili, Brescia, Italy
18EULAR PARE Patient Research Partner, Rome, Italy
19Department of Clinical Sciences and Community Health, University of Milan,
Istituto Auxologico Italiano, Milan, Italy
20Rheumatology Unit, Department of Clinical and Experimental Medicine, University
of Pisa, Pisa, Italy
21Neonatology and Neonatal Intensive Care Unit, Spedali Civili, Brescia, Italy
22Norwegian National Advisory Unit on Pregnancy and Rheumatic Diseases,
St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
23Department of Rheumatology, Iuliu Hatieganu University of Medicine and
Pharmacy, Cluj-Napoca, Romania
24Department of Obstetrics and Gynaecology, University Hospital of Bern, Inselspital,
Switzerland
25Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet,
Karolinska University Hospital, Stockholm, Sweden
26Rheumatology Unit, Joint Academic Rheumatology Programme, 1st Department of
Propaedeutic Internal Medicine Athens, National and Kapodistrian University of
Athens, Athens, Greece
27Department of Rheumatology, Istanbul Bilim University, Istanbul Florence
Nightingale Hospital, Esentepe-Istanbul, Turkey
284th Department of Internal Medicine, ‘Attikon’ University Hospital, Medical School,
University of Athens, Athens, Greece
29Joint Academic Rheumatology Program, National and Kapodestrian University of
Athens, Athens, Greece
Acknowledgements The committee wishes to acknowledge the support of the
EULAR Standing Committee on Clinical Affairs. The committee also expresses its
sincere appreciation and gratitude to the EULAR Secretariat and especially to Patrizia
Jud, executive assistant, for outstanding organisation.
Contributors LA and GKB contributed equally to the article. DB and AT share senior
authorship. All the authors contributed to discussion of the results of the systematic
literature review (performed by LA and GKB) and to the review of the article.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
REFERENCES
1 Østensen M. New insights into sexual functioning and fertility in rheumatic
diseases. Best Pract Res Clin Rheumatol 2004;18:219–32.
2 Ntali S, Damjanov N, Drakakis P, et al. Women’s health and fertility, family
planning and pregnancy in immune-mediated rheumatic diseases: a report from
a south-eastern European Expert Meeting. Clin Exp Rheumatol 2014;32:
959–68.
3 Kavanaugh A, Cush JJ, Ahmed MS, et al. Proceedings from the American College
of Rheumatology Reproductive Health Summit: the management of fertility,
pregnancy, and lactation in women with autoimmune and systemic inﬂammatory
diseases. Arthritis Care Res (Hoboken) 2015;67:313–25.
4 Østensen M, Andreoli L, Brucato A, et al. State of the art: reproduction and
pregnancy in rheumatic diseases. Autoimmun Rev 2015;14:376–86.
5 van der Heijde D, Aletaha D, Carmona L, et al. 2014 Update of the EULAR
standardised operating procedures for EULAR-endorsed recommendations.
Ann Rheum Dis 2015;74:8–13.
6 Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an
update of the classiﬁcation criteria for deﬁnite antiphospholipid syndrome (APS).
J Thromb Haemost 2006;4:295–306.
7 Nalli C, Iodice A, Andreoli L, et al. The effects of lupus and antiphospholipid
antibody syndrome on foetal outcomes. Lupus 2014;23:507–17.
8 Andreoli L, Fredi M, Nalli C, et al. Pregnancy implications for systemic lupus
erythematosus and the antiphospholipid syndrome. J Autoimmun 2012;38:
J197–208.
9 Parke A. Drug exposure, pregnancy outcome and fetal and childhood development
occurring in the offspring of mothers with systemic lupus erythematosus and other
chronic autoimmune diseases. Lupus 2006;15:808–13.
10 Vinet É, Pineau CA, Clarke AE, et al. Neurodevelopmental disorders in children
born to mothers with systemic lupus erythematosus. Lupus 2014;23:1099–104.
11 Nalli C, Iodice A, Andreoli L, et al. Children born to SLE and APS mothers. Lupus
2014;23:1246–8.
12 Mekinian A, Lachassinne E, Nicaise-Roland P, et al. European registry of babies
born to mothers with antiphospholipid syndrome. Ann Rheum Dis
2013;72:217–22.
13 Vinet É, Pineau CA, Clarke AE, et al. Increased risk of autism spectrum disorders
in children born to women with systemic lupus erythematosus: results from a large
population-based cohort. Arthritis Rheumatol 2015;67:3201–8.
14 Yang H, Liu H, Xu D, et al. Pregnancy-related systemic lupus erythematosus:
clinical features, outcome and risk factors of disease ﬂares—a case control study.
PLoS ONE 2014;9:e104375.
15 Kwok LW, Tam LS, Zhu T, et al. Predictors of maternal and fetal outcomes in
pregnancies of patients with systemic lupus erythematosus. Lupus
2011;20:829–36.
16 Roberge S, Giguère Y, Villa P, et al. Early administration of low-dose aspirin for
the prevention of severe and mild preeclampsia: a systematic review and
meta-analysis. Am J Perinatol 2012;29:551–6.
17 Chen TK, Gelber AC, Witter FR, et al. Renal biopsy in the management of lupus
nephritis during pregnancy. Lupus 2015;24:147–54.
18 Le Thi Huong D, Wechsler B, Piette JC, et al. Pregnancy and its outcome in
systemic lupus erythematosus. QJM 1994;87:721–9.
19 Buyon JP, Kim MY, Guerra MM, et al. Predictors of pregnancy outcomes in
patients with lupus: a cohort study. Ann Intern Med 2015;163:153–63.
20 Clowse ME, Magder LS, Witter F, et al. The impact of increased lupus activity on
obstetric outcomes. Arthritis Rheum 2005;52:514–21.
21 Mok MY, Leung PY, Lao TH, et al. Clinical predictors of fetal and maternal
outcome in Chinese patients with systemic lupus erythematosus. Ann Rheum Dis
2004;63:1705–6.
22 Chakravarty EF, Colón I, Langen ES, et al. Factors that predict prematurity and
preeclampsia in pregnancies that are complicated by systemic lupus erythematosus.
Am J Obstet Gynecol 2005;192:1897–904.
23 Imbasciati E, Tincani A, Gregorini G, et al. Pregnancy in women with pre-existing
lupus nephritis: predictors of fetal and maternal outcome. Nephrol Dial Transplant
2009;24:519–25.
24 Al Arfaj AS, Khalil N. Pregnancy outcome in 396 pregnancies in patients with SLE
in Saudi Arabia. Lupus 2010;19:1665–73.
25 Smyth A, Oliveira GH, Lahr BD, et al. A systematic review and meta-analysis of
pregnancy outcomes in patients with systemic lupus erythematosus and lupus
nephritis. Clin J Am Soc Nephrol 2010;5:2060–8.
26 Shibata S, Sasaki T, Hirabayashi Y, et al. Risk factors in the pregnancy of patients
with systemic lupus erythematosus: association of hypocomplementaemia with
poor prognosis. Ann Rheum Dis 1992;51:619–23.
27 Cortes-Hernandez J, Ordi-Ros J, Paredes F, et al. Clinical predictors of fetal and
maternal outcome in systemic lupus erythematosus: a prospective study of 103
pregnancies. Rheumatology (Oxford) 2002;41:643–50.
28 Bouvier S, Cochery-Nouvellon E, Lavigne-Lissalde G, et al. Comparative incidence
of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the
NOH-APS observational study. Blood 2014;123:404–13.
29 Jeremic K, Stefanovic A, Dotlic J, et al. Neonatal outcome in pregnant patients
with antiphospholipid syndrome. J Perinat Med 2015;43:761–8.
30 Girón-González JA, García del Río E, Rodríguez C, et al. Antiphospholipid
syndrome and asymptomatic carriers of antiphospholipid antibody: prospective
analysis of 404 individuals. J Rheumatol 2004;31:1560–7.
31 Ruffatti A, Tonello M, Visentin MS, et al. Risk factors for pregnancy failure in
patients with anti-phospholipid syndrome treated with conventional
therapies: a multicentre, case-control study. Rheumatology (Oxford)
2011;50:1684–9.
32 Danowski A, de Azevedo MN, de Souza Papi JA, et al. Determinants of risk for
venous and arterial thrombosis in primary antiphospholipid syndrome and in
antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol
2009;36:1195–9.
33 Clowse ME, Magder L, Witter F, et al. Hydroxychloroquine in lupus pregnancy.
Arthritis Rheum 2006;54:3640–7.
34 Lockshin MD, Kim M, Laskin CA, et al. Prediction of adverse pregnancy outcome
by the presence of lupus anticoagulant, but not anticardiolipin antibody, in
patients with antiphospholipid antibodies. Arthritis Rheum 2012;64:2311–18.
35 Stone S, Hunt BJ, Khamashta MA, et al. Primary antiphospholipid syndrome in
pregnancy: an analysis of outcome in a cohort of 33 women treated with a
rigorous protocol. J Thromb Haemost 2005;3:243–5.
36 Abou-Nassar K, Carrier M, Ramsay T, et al. The association between
antiphospholipid antibodies and placenta mediated complications: a systematic
review and meta-analysis. Thromb Res 2011;128:77–85.
37 Chauleur C, Galanaud JP, Alonso S, et al. Observational study of pregnant women
with a previous spontaneous abortion before the 10th gestation week with and
without antiphospholipid antibodies. J Thromb Haemost 2010;8:699–706.
38 Ruffatti A, Calligaro A, Hoxha A, et al. Laboratory and clinical features of pregnant
women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res
(Hoboken) 2010;62:302–7.
39 Simchen MJ, Dulitzki M, Rofe G, et al. High positive antibody titers and adverse
pregnancy outcome in women with antiphospholipid syndrome. Acta Obstet
Gynecol Scand 2011;90:1428–33.
40 Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of
hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/
Recommendations
482 Andreoli L, et al. Ann Rheum Dis 2017;76:476–485. doi:10.1136/annrheumdis-2016-209770
group.bmj.com on May 10, 2017 - Published by http://ard.bmj.com/Downloaded from 
Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation
2012;126:76–82.
41 Brucato A, Frassi M, Franceschini F, et al. Risk of congenital complete heart block
in newborns of mothers with anti-Ro/SSA antibodies detected by
counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis
Rheum 2001;44:1832–5.
42 Cimaz R, Spence DL, Hornberger L, et al. Incidence and spectrum of neonatal
lupus erythematosus: a prospective study of infants born to mothers with anti-Ro
autoantibodies. J Pediatr 2003;142:678–83.
43 Costedoat-Chalumeau N, Amoura Z, Lupoglazoff JM, et al. Outcome of
pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies,
with special focus on electrocardiographic variations in the children and
comparison with a control group. Arthritis Rheum 2004;50:3187–94.
44 Barnado A, Wheless L, Meyer AK, et al. Pregnancy outcomes among
African-American patients with systemic lupus erythematosus compared with
controls. Lupus Sci Med 2014;1:e000020.
45 Andrade RM, McGwin G Jr, Alarcón GS, et al. Predictors of post-partum damage
accrual in systemic lupus erythematosus: data from LUMINA, a multiethnic US
cohort (XXXVIII). Rheumatology (Oxford) 2006;45:1380–4.
46 Lv J, Wang W, Li Y. Clinical outcomes and predictors of fetal and maternal
consequences of pregnancy in lupus nephritis patients. Int Urol Nephrol
2015;47:1379–85.
47 Moore LE. Recurrent risk of adverse pregnancy outcome. Obstet Gynecol Clin
North Am 2008;35:459–71.
48 Borella E, Lojacono A, Gatto M, et al. Predictors of maternal and fetal
complications in SLE patients: a prospective study. Immunol Res 2014;60:170–6.
49 Molad Y, Borkowski T, Monselise A, et al. Maternal and fetal outcome of lupus
pregnancy: a prospective study of 29 pregnancies. Lupus 2005;14:145–51.
50 Stagnaro-Green A, Akhter E, Yim C, et al. Thyroid disease in pregnant women
with systemic lupus erythematosus: increased preterm delivery. Lupus
2011;20:690–9.
51 Shand AW, Algert CS, March L, et al. Second pregnancy outcomes for women
with systemic lupus erythematosus. Ann Rheum Dis 2013;72:547–51.
52 Bramham K, Hunt BJ, Bewley S, et al. Pregnancy outcomes in systemic lupus
erythematosus with and without previous nephritis. J Rheumatol
2011;38:1906–13.
53 Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and
immunologic manifestations and patterns of disease expression in a cohort of
1,000 patients. Arthritis Rheum 2002;46:1019–27.
54 Alijotas-Reig J, Ferrer-Oliveras R, Ruffatti A, et al. The European Registry on
Obstetric Antiphospholipid Syndrome (EUROAPS): a survey of 247 consecutive
cases. Autoimmun Rev 2015;14:387–95.
55 Liu LL, Jiang Y, Wang LN, et al. Efﬁcacy and safety of mycophenolate mofetil
versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis
of randomized controlled trials. Drugs 2012;72:1521–33.
56 Koh JH, Ko HS, Kwok SK, et al. Hydroxychloroquine and pregnancy on lupus ﬂares
in Korean patients with systemic lupus erythematosus. Lupus 2015;24:210–17.
57 Wagner SJ, Craici I, Reed D, et al. Maternal and foetal outcomes in pregnant
patients with active lupus nephritis. Lupus 2009;18:342–7.
58 Clark CA, Spitzer KA, Nadler JN, et al. Preterm deliveries in women with systemic
lupus erythematosus. J Rheumatol 2003;30:2127–32.
59 Fischer-Betz R, Specker C, Brinks R, et al. Low risk of renal ﬂares and negative
outcomes in women with lupus nephritis conceiving after switching from
mycophenolate mofetil to azathioprine. Rheumatology (Oxford) 2013;52:
1070–6.
60 Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in lupus
pregnancy: double-blind and placebo-controlled study. Lupus 2001;10:401–4.
61 WHO Guidelines Approved by the Guidelines Review Committee. Medical Eligibility
Criteria for Contraceptive Use: A WHO Family Planning Cornerstone. Geneva:
World Health Organization, 2010. http://apps.who.int/iris/bitstream/10665/
181468/1/9789241549158_eng.pdf
62 Pisoni CN, Cuadrado MJ, Khamashta MA, et al. Treatment of menorrhagia
associated with oral anticoagulation: efﬁcacy and safety of the levonorgestrel
releasing intrauterine device (Mirena coil). Lupus 2006;15:877–80.
63 Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with
systemic lupus erythematosus. N Engl J Med 2005;353:2550–8.
64 Sánchez-Guerrero J, Uribe AG, Jiménez-Santana L, et al. A trial of contraceptive
methods in women with systemic lupus erythematosus. N Engl J Med
2005;353:2539–49.
65 Urbanus RT, Siegerink B, Roest M, et al. Antiphospholipid antibodies and risk of
myocardial infarction and ischaemic stroke in young women in the RATIO study:
a case-control study. Lancet Neurol 2009;8:998–1005.
66 Clowse ME, Chakravarty E, Costenbader KH, et al. Effects of infertility, pregnancy
loss, and patient concerns on family size of women with rheumatoid arthritis and
systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012;64:668–74.
67 Ekblom-Kullberg S, Kautiainen H, Alha P, et al. Reproductive health in women
with systemic lupus erythematosus compared to population controls. Scand J
Rheumatol 2009;38:375–80.
68 Morel N, Bachelot A, Chakhtoura Z, et al. Study of anti-Müllerian hormone and its
relation to the subsequent probability of pregnancy in 112 patients with systemic
lupus erythematosus, exposed or not to cyclophosphamide. J Clin Endocrinol
Metab 2013;98:3785–92.
69 Velarde-Ochoa Mdel C, Esquivel-Valerio JA, Vega-Morales D, et al. Anti-Müllerian
hormone in reproductive age women with systemic lupus erythematosus. Reumatol
Clin 2015;11:78–82.
70 Boumpas DT, Austin HA III, Vaughan EM, et al. Risk for sustained amenorrhea in
patients with systemic lupus erythematosus receiving intermittent pulse
cyclophosphamide therapy. Ann Intern Med 1993;119:366–9.
71 Ioannidis JP, Katsiﬁs GE, Tzioufas AG, et al. Predictors of sustained amenorrhea
from pulsed intravenous cyclophosphamide in premenopausal women with
systemic lupus erythematosus. J Rheumatol 2002;29:2129–35.
72 Houssiau FA, Vasconcelos C, D’Cruz D, et al. The 10-year follow-up data of the
Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous
cyclophosphamide. Ann Rheum Dis 2010;69:61–4.
73 Practice Committee of American Society for Reproductive Medicine. Diagnostic
evaluation of the infertile female: a committee opinion. Fertil Steril 2015;103:
e44–50.
74 Henes M, Henes JC, Neunhoeffer E, et al. Fertility preservation methods in young
women with systemic lupus erythematosus prior to cytotoxic therapy: experiences
from the FertiPROTEKT network. Lupus 2012;21:953–8.
75 Elizur SE, Chian RC, Pineau CA, et al. Fertility preservation treatment for young
women with autoimmune diseases facing treatment with gonadotoxic agents.
Rheumatology (Oxford) 2008;47:1506–9.
76 Ben-Aharon I, Gafter-Gvili A, Leibovici L, et al. Pharmacological interventions for
fertility preservation during chemotherapy: a systematic review and meta-analysis.
Breast Cancer Res Treat 2010;122:803–11.
77 Blumenfeld Z, Zur H, Dann EJ. Gonadotropin-releasing hormone agonist
cotreatment during chemotherapy may increase pregnancy rate in survivors.
Oncologist 2015;20:1283–9.
78 Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during
breast-cancer adjuvant chemotherapy. N Engl J Med 2015;372:923–32.
79 Brunner HI, Silva CA, Reiff A, et al. Randomized, double-blind, dose-escalation
trial of triptorelin for ovary protection in childhood-onset systemic lupus
erythematosus. Arthritis Rheumatol 2015;67:1377–85.
80 Guballa N, Sammaritano L, Schwartzman S, et al. Ovulation induction and in vitro
fertilization in systemic lupus erythematosus and antiphospholipid syndrome.
Arthritis Rheum 2000;43:550–6.
81 Huong DL, Wechsler B, Vauthier-Brouzes D, et al. Importance of planning
ovulation induction therapy in systemic lupus erythematosus and antiphospholipid
syndrome: a single center retrospective study of 21 cases and 114 cycles. Semin
Arthritis Rheum 2002;32:174–88.
82 Ragab A, Barakat R, Ragheb M, et al. Subfertility treatment in women with
systemic lupus erythematosus. J Obstet Gynaecol 2012;32:569–71.
83 Orquevaux P, Masseau A, Le Guern V, et al. [In vitro fertilization and systemic
lupus erythematosus or antiphospholipid syndrome: an update]. Rev Med Interne
2015;36:154–8.
84 Bellver J, Pellicer A. Ovarian stimulation for ovulation induction and in vitro
fertilization in patients with systemic lupus erythematosus and antiphospholipid
syndrome. Fertil Steril 2009;92:1803–10.
85 Ruiz-Irastorza G, Khamashta MA, Gordon C, et al. Measuring systemic lupus
erythematosus activity during pregnancy: validation of the lupus activity index in
pregnancy scale. Arthritis Rheum 2004;51:78–82.
86 Yee CS, Akil M, Khamashta M, et al. The BILAG2004-Pregnancy index is reliable
for assessment of disease activity in pregnant SLE patients. Rheumatology (Oxford)
2012;51:1877–80.
87 Gordon C. Pregnancy and autoimmune diseases. Best Pract Res Clin Rheumatol
2004;18:359–79.
88 Buyon JP, Cronstein BN, Morris M, et al. Serum complement values (C3 and C4)
to differentiate between systemic lupus activity and pre-eclampsia. Am J Med
1986;81:194–200.
89 Tomer Y, Viegas OA, Swissa M, et al. Levels of lupus autoantibodies in pregnant
SLE patients: correlations with disease activity and pregnancy outcome. Clin Exp
Rheumatol 1996;14:275–80.
90 Clowse ME, Magder LS, Petri M. The clinical utility of measuring complement and
anti-dsDNA antibodies during pregnancy in patients with systemic lupus
erythematosus. J Rheumatol 2011;38:1012–16.
91 Kobayashi N, Yamada H, Kishida T, et al. Hypocomplementemia correlates with
intrauterine growth retardation in systemic lupus erythematosus. Am J Reprod
Immunol 1999;42:153–9.
92 Clowse ME, Wallace DJ, Weisman M, et al. Predictors of preterm birth in
patients with mild systemic lupus erythematosus. Ann Rheum Dis
2013;72:1536–9.
93 Lees C, Marlow N, Arabin B, et al. Perinatal morbidity and mortality in
early-onset fetal growth restriction: cohort outcomes of the trial of randomized
umbilical and fetal ﬂow in Europe (TRUFFLE). Ultrasound Obstet Gynecol
2013;42:400–8.
Recommendations
483Andreoli L, et al. Ann Rheum Dis 2017;76:476–485. doi:10.1136/annrheumdis-2016-209770
group.bmj.com on May 10, 2017 - Published by http://ard.bmj.com/Downloaded from 
94 Lees CC, Marlow N, van Wassenaer-Leemhuis A, et al. 2 year neurodevelopmental
and intermediate perinatal outcomes in infants with very preterm fetal growth
restriction (TRUFFLE): a randomised trial. Lancet 2015;385:2162–72.
95 Alﬁrevic Z, Stampalija T, Gyte GM. Fetal and umbilical Doppler ultrasound in
high-risk pregnancies. Cochrane Database Syst Rev 2013;11:CD007529.
96 Figueras F, Savchev S, Triunfo S, et al. An integrated model with classiﬁcation
criteria to predict small-for-gestational-age fetuses at risk of adverse perinatal
outcome. Ultrasound Obstet Gynecol 2015;45:279–85.
97 Sovio U, White IR, Dacey A, et al. Screening for fetal growth restriction with
universal third trimester ultrasonography in nulliparous women in the Pregnancy
Outcome Prediction (POP) study: a prospective cohort study. Lancet
2015;386:2089–97.
98 Brito-Zerón P, Izmirly PM, Ramos-Casals M, et al. The clinical spectrum of
autoimmune congenital heart block. Nat Rev Rheumatol 2015;11:301–12.
99 Saxena A, Izmirly PM, Mendez B, et al. Prevention and treatment in utero of
autoimmune-associated congenital heart block. Cardiol Rev 2014;22:263–7.
100 Friedman DM, Kim MY, Copel JA, et al. Prospective evaluation of fetuses with
autoimmune-associated congenital heart block followed in the PR Interval and
Dexamethasone Evaluation (PRIDE) Study. Am J Cardiol 2009;103:1102–6.
101 Izmirly PM, Saxena A, Kim MY, et al. Maternal and fetal factors associated with
mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated
cardiac neonatal lupus. Circulation 2011;124:1927–35.
102 Eliasson H, Sonesson SE, Sharland G, et al. Isolated atrioventricular block in the
fetus: a retrospective, multinational, multicenter study of 175 patients. Circulation
2011;124:1919–26.
103 Levesque K, Morel N, Maltret A, et al. Description of 214 cases of autoimmune
congenital heart block: Results of the French neonatal lupus syndrome.
Autoimmun Rev 2015;14:1154–60.
104 Izmirly PM, Saxena A, Sahl SK, et al. Assessment of ﬂuorinated steroids to avert
progression and mortality in anti-SSA/Ro-associated cardiac injury limited to the
fetal conduction system. Ann Rheum Dis 2016;75:1161-5.
105 Tingström J, Hjelmstedt A, Welin Henriksson E, et al. Ro/SSA autoantibody-positive
pregnancy: reactions to serial fetal Doppler echocardiographic surveillance. Lupus
2015;24:1540–5.
106 Derksen RH, Bruinse HW, de Groot PG, et al. Pregnancy in systemic lupus
erythematosus: a prospective study. Lupus 1994;3:149–55.
107 Al Maimouni H, Gladman DD, Ibañez D, et al. Switching treatment between
mycophenolate mofetil and azathioprine in lupus patients: indications and
outcomes. Arthritis Care Res (Hoboken) 2014;66:1905–9.
108 Hussein MM, Mooij JM, Roujouleh H. Cyclosporine in the treatment of lupus
nephritis including two patients treated during pregnancy. Clin Nephrol
1993;40:160–3.
109 Webster P, Wardle A, Bramham K, et al. Tacrolimus is an effective treatment for
lupus nephritis in pregnancy. Lupus 2014;23:1192–6.
110 Moroni G, Quaglini S, Banﬁ G, et al. Pregnancy in lupus nephritis. Am J Kidney
Dis 2002;40:713–20.
111 Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to
consider for use of antirheumatic drugs before pregnancy, and during pregnancy
and lactation. Ann Rheum Dis 2016;75:795–810.
112 Abou-Nassar K, Karsh J, Giulivi A, et al. Successful prevention of thrombotic
thrombocytopenic purpura (TTP) relapse using monthly prophylactic plasma
exchanges throughout pregnancy in a patient with systemic lupus erythematosus
and a prior history of refractory TTP and recurrent fetal loss. Transfus Apher Sci
2010;43:29–31.
113 Takeshita Y, Turumi Y, Touma S, et al. Successful delivery in a pregnant woman
with lupus anticoagulant positive systemic lupus erythematosus treated with
double ﬁltration plasmapheresis. Ther Apher 2001;5:22–4.
114 Cavallasca JA, Laborde HA, Ruda-Vega H, et al. Maternal and fetal outcomes of
72 pregnancies in Argentine patients with systemic lupus erythematosus (SLE).
Clin Rheumatol 2008;27:41–6.
115 Danve A, Perry L, Deodhar A. Use of belimumab throughout pregnancy to treat
active systemic lupus erythematosus: a case report. Semin Arthritis Rheum
2014;44:195–7.
116 Østensen M, Förger F. How safe are anti-rheumatic drugs during pregnancy? Curr
Opin Pharmacol 2013;13:470–5.
117 Flint J, Panchal S, Hurrell A, et al. BSR and BHPR guideline on prescribing drugs in
pregnancy and breastfeeding-Part I: standard and biologic disease modifying
anti-rheumatic drugs and corticosteroids. Rheumatology 2016 [epub ahead of print].
118 Flint J, Panchal S, Hurrell A, et al. BSR and BHPR guideline on prescribing drugs in
pregnancy and breastfeeding-Part II: analgesics and other drugs used in
rheumatology practice. Rheumatology 2016. [epub ahead of print].
119 Sciascia S, Hunt BJ, Talavera-Garcia E, et al. The impact of hydroxychloroquine
treatment on pregnancy outcome in women with antiphospholipid antibodies.
Am J Obstet Gynecol 2016;214:273.e1-8. [epub ahead of print].
120 Sciascia S, Branch DW, Levy RA, et al. The efﬁcacy of hydroxychloroquine in
altering pregnancy outcome in women with antiphospholipid antibodies. Evidence
and clinical judgment. Thromb Haemost 2016;115:285–90.
121 Mekinian A, Lazzaroni MG, Kuzenko A, et al. The efﬁcacy of
hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome:
data from a European multicenter retrospective study. Autoimmun Rev
2015;14:498–502.
122 Tunks RD, Clowse ME, Miller SG, et al. Maternal autoantibody levels in congenital
heart block and potential prophylaxis with antiinﬂammatory agents. Am J Obstet
Gynecol 2013;208:64.e1-7.
123 Roberge S, Villa P, Nicolaides K, et al. Early administration of low-dose aspirin for
the prevention of preterm and term preeclampsia: a systematic review and
meta-analysis. Fetal Diagn Ther 2012;31:141–6.
124 Wu CQ, Kustec VE, Brown RN, et al. The medical management of
antiphospholipid syndrome in pregnancy: a meta-analysis. Obstet Gynecol
2014;123(Suppl 1):178s–9s.
125 Mak A, Cheung MW, Cheak AA, et al. Combination of heparin and aspirin is
superior to aspirin alone in enhancing live births in patients with recurrent
pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of
randomized controlled trials and meta-regression. Rheumatology (Oxford)
2010;49:281–8.
126 Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid
syndrome with recurrent pregnancy loss: a systematic review and meta-analysis.
Obstet Gynecol 2010;115:1256–62.
127 de Jesús GR, Rodrigues G, de Jesús NR, et al. Pregnancy morbidity in
antiphospholipid syndrome: what is the impact of treatment? Curr Rheumatol Rep
2014;16:403.
128 Ruffatti A, Gervasi MT, Favaro M, et al. Adjusted prophylactic doses of nadroparin
plus low dose aspirin therapy in obstetric antiphospholipid syndrome. A
prospective cohort management study. Clin Exp Rheumatol 2011;29:551–4.
129 Fouda UM, Sayed AM, Abdou AM, et al. Enoxaparin versus unfractionated heparin
in the management of recurrent abortion secondary to antiphospholipid syndrome.
Int J Gynaecol Obstet 2011;112:211–15.
130 Ruffatti A, Salvan E, Del Ross T, et al. Treatment strategies and pregnancy
outcomes in antiphospholipid syndrome patients with thrombosis and triple
antiphospholipid positivity. A European multicentre retrospective study. Thromb
Haemost 2014;112:727–35.
131 Bramham K, Thomas M, Nelson-Piercy C, et al. First-trimester low-dose
prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood
2011;117:6948–51.
132 Fischer-Betz R, Specker C, Brinks R, et al. Pregnancy outcome in patients with
antiphospholipid syndrome after cerebral ischaemic events: an observational study.
Lupus 2012;21:1183–9.
133 Le Thi Thuong D, Tieulié N, Costedoat N, et al. The HELLP syndrome in the
antiphospholipid syndrome: retrospective study of 16 cases in 15 women.
Ann Rheum Dis 2005;64:273–8.
134 Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and
progesterone hormone replacement therapy on disease activity in
systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005;142
(Pt 1):953–62. http://dx.doi.org/10.7326/0003-4819-142-12_Part_
1-200506210-00004
135 Sánchez-Guerrero J, Gonzalez-Perez M, Durand-Carbajal M, et al. Menopause
hormonal therapy in women with systemic lupus erythematosus. Arthritis Rheum
2007;56:3070–9.
136 Cravioto MD, Durand-Carbajal M, Jiménez-Santana L, et al. Efﬁcacy of estrogen
plus progestin on menopausal symptoms in women with systemic lupus
erythematosus: a randomized, double-blind, controlled trial. Arthritis Care Res
(Hoboken) 2011;63:1654–63.
137 Hochman J, Urowitz MB, Ibañez D, et al. Hormone replacement therapy in women
with systemic lupus erythematosus and risk of cardiovascular disease. Lupus
2009;18:313–17.
138 Fernandez M, Calvo-Alen J, Bertoli AM, et al. Systemic lupus erythematosus in a
multiethnic US cohort (LUMINA L II): relationship between vascular events and the
use of hormone replacement therapy in postmenopausal women. J Clin Rheumatol
2007;13:261–5.
139 Drake MT, Clarke BL, Lewiecki EM. The pathophysiology and treatment of
osteoporosis. Clin Ther 2015;37:1837–50.
140 Sarri G, Davies M, Lumsden MA. Diagnosis and management of menopause:
summary of NICE guidance. BMJ 2015;351:h5746.
141 National Collaborating Centre for Ws, Children’s H. National Institute for Health
and Clinical Excellence: Guidance. Menopause: Full Guideline. London: National
Institute for Health and Care Excellence (UK) Copyright (c) 2015 National
Collaborating Centre for Women’s and Children’s Health, 2015. https://www.nice.
org.uk/guidance/ng23/evidence/appendices-ag-559549262
142 Bernatsky S, Ramsey-Goldman R, Foulkes WD, et al. Breast, ovarian, and
endometrial malignancies in systemic lupus erythematosus: a meta-analysis. Br J
Cancer 2011;104:1478–81.
143 Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic
lupus: an updated international multi-centre cohort study. J Autoimmun
2013;42:130–5.
Recommendations
484 Andreoli L, et al. Ann Rheum Dis 2017;76:476–485. doi:10.1136/annrheumdis-2016-209770
group.bmj.com on May 10, 2017 - Published by http://ard.bmj.com/Downloaded from 
144 Liu H, Ding Q, Yang K, et al. Meta-analysis of systemic lupus erythematosus and
the risk of cervical neoplasia. Rheumatology (Oxford) 2011;50:343–8.
145 Santana IU, Gomes Ado N, Lyrio LD, et al. Systemic lupus erythematosus, human
papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic
review. Clin Rheumatol 2011;30:665–72.
146 Zard E, Arnaud L, Mathian A, et al. Increased risk of high grade cervical squamous
intraepithelial lesions in systemic lupus erythematosus: a meta-analysis of the
literature. Autoimmun Rev 2014;13:730–5.
147 Dreyer L, Faurschou M, Mogensen M, et al. High incidence of potentially
virus-induced malignancies in systemic lupus erythematosus: a long-term followup
study in a Danish cohort. Arthritis Rheum 2011;63:3032–7.
148 Bateman H, Yazici Y, Leff L, et al. Increased cervical dysplasia in intravenous
cyclophosphamide-treated patients with SLE: a preliminary study. Lupus
2000;9:542–4.
149 Bernatsky S, Ramsey-Goldman R, Gordon C, et al. Factors associated with
abnormal Pap results in systemic lupus erythematosus. Rheumatology (Oxford)
2004;43:1386–9.
150 Ognenovski VM, Marder W, Somers EC, et al. Increased incidence of cervical
intraepithelial neoplasia in women with systemic lupus erythematosus treated
with intravenous cyclophosphamide. J Rheumatol 2004;31:1763–7.
151 Klumb EM, Araujo ML Jr, Jesus GR, et al. Is higher prevalence of cervical
intraepithelial neoplasia in women with lupus due to immunosuppression?
J Clin Rheumatol 2010;16:153–7.
152 Bernatsky SR, Cooper GS, Mill C, et al. Cancer screening in patients with systemic
lupus erythematosus. J Rheumatol 2006;33:45–9.
153 Yazdany J, Tonner C, Trupin L, et al. Provision of preventive health care in systemic
lupus erythematosus: data from a large observational cohort study. Arthritis Res
Ther 2010;12:R84.
154 Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for
quadrivalent human papillomavirus recombinant vaccine. JAMA 2009;302:750–7.
155 Soybilgic A, Onel KB, Utset T, et al. Safety and immunogenicity of the quadrivalent
HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26
years. Pediatr Rheumatol Online J 2013;11:29.
156 Mok CC, Ho LY, Fong LS, et al. Immunogenicity and safety of a quadrivalent
human papillomavirus vaccine in patients with systemic lupus erythematosus: a
case-control study. Ann Rheum Dis 2013;72:659–64.
157 Soldevilla HF, Briones SF, Navarra SV. Systemic lupus erythematosus following HPV
immunization or infection? Lupus 2012;21:158–61.
158 Gatto M, Agmon-Levin N, Soriano A, et al. Human papillomavirus vaccine and
systemic lupus erythematosus. Clin Rheumatol 2013;32:1301–7.
159 Baker B, Eça Guimarães L, Tomljenovic L, et al. The safety of human papilloma
virus-blockers and the risk of triggering autoimmune diseases. Expert Opin Drug
Saf 2015;14:1387–94.
160 van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for
vaccination in adult patients with autoimmune inﬂammatory rheumatic diseases.
Ann Rheum Dis 2011;70:414–22.
Recommendations
485Andreoli L, et al. Ann Rheum Dis 2017;76:476–485. doi:10.1136/annrheumdis-2016-209770
group.bmj.com on May 10, 2017 - Published by http://ard.bmj.com/Downloaded from 
syndrome
erythematosus and/or antiphospholipid
menopause in patients with systemic lupus 
assisted reproduction, pregnancy and
and the management of family planning, 
EULAR recommendations for women's health
E Svenungsson, M Tektonidou, S Yavuz, D Boumpas and A Tincani
Meroni, M Mosca, M Motta, M Ostensen, C Pamfil, L Raio, M Schneider, 
Moraes-Fontes, M Khamashta, J King, A Lojacono, F Marchiori, P L
Costedoat-Chalumeau, A Doria, R Fischer-Betz, F Forger, M F 
L Andreoli, G K Bertsias, N Agmon-Levin, S Brown, R Cervera, N
doi: 10.1136/annrheumdis-2016-209770
2016
2017 76: 476-485 originally published online July 25,Ann Rheum Dis 
 http://ard.bmj.com/content/76/3/476
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://ard.bmj.com/content/76/3/476
This article cites 156 articles, 40 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (597)Open access
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on May 10, 2017 - Published by http://ard.bmj.com/Downloaded from 
